Table 4.

Serious skin disorders and hypersensitivity reactions occurring in patients in the vemurafenib early post-marketing phase vigilance study

Case no.	Events	Prior therapy	Outcome	Re-administration of vemurafenib
1	Skin disorder	Pembrolizumab until Day −28	Recovered	Yes
2	Hypersensitivitya	Nivolumab until Day −5	Improved	Yes
3	Rash	Interferon beta	Recovered	Yes
4	Drug eruption	Nivolumab until Day −21	Improved	Yes
5	Stevens–Johnson syndrome	Nivolumab until Day −21	Improved	No
6	Erythema multiforme	Nivolumab until Day −35	Recovered	Yes
7	Drug eruption	Nivolumab until Day −35	Recovered	No

^aPreviously reported by Imafuku et al. [15]. This patient experienced three hypersensitivity episodes